Presentations and Posters
Predicting pathological complete response by the combination of microRNAs in patients with HER2-positive primary breast cancer who received neoadjuvant combination therapy of trastuzumab, lapatinib and paclitaxel: Results from JBCRG-16 (NeoLath) study.
Akihiko Shimomura, Norikazu Masuda, Junpei Kawauchi, Satoko Takizawa, Makiko Ichikawa, Juntaro Matasuzaki, Katsumasa Kuroi, Hisato Hara, Naohito Yamamoto, Kenichi Inoue, Nobuyasu Suganuma, Kenjiro Aogi, Shinji Ohno, Kenji Tamura, Takahiro Ochiya, Masakazu Toi
2018.12 SABCS Poster San Antonio, USA
A phase III trial to compare eribulin mesylate + trastuzumab (H) + pertuzumab (P) with paclitaxel or docetaxel + HP for HER2-positive advanced or metastatic breast cancer (JBCRG-M06 / EMERALD)
Norikazu Masuda, Toshinari Yamashita, Shigehira Saji, Kazuhiro Araki, Yoshinori Ito, Toshimi Takano, Masato Takahashi, Junji Tsurutani, Kei Koizumi, Masahiro Kitada, Yasuyuki Kojima, Yasuaki Sagara, Hiroshi Tada, Tsutomu Iwasa, Takayuki Kadoya, Tsuguo Iwatani, Hiroki Hasegawa, Satoshi Morita, Shinji Ohno
2018.12 SABCS Poster San Antonio, USA
Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 8-12 weeks’ exemestane exposure for ER+/HER2-postmenopausal breast cancer patients (JBCRG-11TC)
Hiroyuki Yasojima, Nobuaki Sato, Norikazu Masuda, Takashi Morimoto, Takayuki Ueno, Chizuko Kanbayashi, Koji Kaneko, Shigehira Saji, Hironobu Sasano, Satoshi Morita, Shinji Ohno, and Masakazu Toi
2018.12 SABCS Poster San Antonio, USA
Tailored neoadjuvant endocrine and chemo-endocrine therapy for postmenopausal patients with estrogen receptor-positive human epidermal growth factor receptor 2-negative primary breast cancer
Norikazu Masuda, Nobuaki Sato, Takashi Morimoto, Takayuki Ueno, Chizuko Kanbayashi, Koji Kaneko, Hiroyuki Yasojima, Shigehira Saji, Hironobu Sasano, Satoshi Morita, Shinji Ohno, Masakazu Toi
2017.12 SABCS poster San Antonio, USA
Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with postmenopausal estrogen receptor-positive advanced/metastatic breast cancer: A subgroup analysis (JBCRG-C06)
Kenjiro Aogi, Hidetoshi Kawaguchi, Norikazu Masuda, Takahiro Nakayama, Yoshinori Ito, Shoichiro Ohtani, Nobuaki Sato, Shigehira Saji, Toshimi Takano Eriko Tokunaga, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Hiroko Yamashita, Toshinari Yamashita, Yutaka Yamamoto, Daisuke Yotsumoto, Masakazu Toi and Shinji Ohno
2017.9 ESMO Poster Madrid
Neoadjuvant therapy with trastuzumab emtansine and pertuzumab in patients with HER2-positive primary breast cancer (A randomized, phase 2 study; JBCRG-20)
Norikazu Masuda, Shoichiro Ohtani, Toshimi Takano, Kenichi Inoue, Eiji Suzuki, Rikiya Nakamura, Hiroko Bando, Yoshinori Ito, Kazushige Ishida, Takashi Yamanaka, Katsumasa Kuroi, Hiroyuki Yasojima, Hiroi Kasai, Tsuyoshi Takasuka, Takaki Sakurai, Tatsuki R. Kataoka, Satoshi Morita, Shinji Ohno, Masakazu Toi
2017.9 ESMO Poster Madrid
Eribulin in combination with pertuzumab plus trastuzumab for HER2-positive advanced or recurrent breast cancer (JBCRG-M03)
Kazutaka Narui, Toshinari Yamashita, Masahiro Kitada, Hidetoshi Kawaguchi, Masaya Hattori, Tetsuhiro Yoshinami, Nobuki Matsunami, Kazuhiro Yanagihara, Teru Kawasoe, Takeshi Nagashima, Hiroko Bando, Hiroshi Yano, Yoshie Hasegawa, Rikiya Nakamura, Masahiro Kashiwaba, Norikazu Masuda, Satoshi Morita, Shinji Ohno, Masakazu Toi
2017年6月 ASCO Poster Chicago
Duration of fasting before taking lapatinib is associated with skin toxicity in neoadjuvant treatment of HER2 positive breast cancer: A cohort study from JBCRG-16/Neo-LaTH
Moe Tsuda, Hiroshi Ishiguro, Naoko Toriguchi, Norikazu Masuda, Hiroko Bando, Oogami Masahiro, Honma Masato, Satoru Shimizu, Naohito Yamamoto, Katsumasa Kuroi, Yasuhiro Yanagita, Toshimi Takano, Satoshi Morita, Masakazu Toi
2016.12 SABCS Poster San Antonio, Texas
Analysis of tumor infiltrating lymphocytes in HER2-positive primary breast cancer treated with neoadjuvant lapatinib and trastuzumab: The NeoLath study (JBCRG-16)
Kosuke Kawaguchi, Eiji Suzuki, Tatsuki R Kataoka, Masahiro Hirata, Shinji Ohno, Hiroko Bando, Hiroshi Ishiguro, Kenichi Inoue, Naohito Yamamoto, Katsumasa Kuroi, Satoshi Morita, Norikazu Masuda, Masakazu Toi, Japan Breast Cancer Research Group (JBCRG)
2016 ASCO Poster
PRECIOUS: A randomized, open-label phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients who were previously treated with pertuzumab, trastuzumab, and chemotherapy (JBCRG-M05).
Yutaka Yamamoto, Hiroji Iwata, Takayuki Ueno, Masahiro Kashiwaba, Naruto Taira, Masato Takahashi, Hiroshi Tada, Koichiro Tsugawa, Tatsuya Toyama, Naoki Niikura, Fumitaka Hara, Tomomi Fujisawa, Tetsuhiro Yoshinami, Shigehira Saji, Toshimi Takano, Norikazu Masuda, Satoshi Morita, Masakazu Toi, Shinji Ohno.
2016 ASCO Poster
by Voluntary Organization JBCRG